Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

M. Stein, Eytan; D. DiNardo, Courtney; A. Pollyea, Daniel; T. Fathi, Amir; J. Roboz, Gail; K. Altman, Jessica; M. Stone, Richard; J. DeAngelo, Daniel; L. Levine, Ross; W. Flinn, Ian; M. Kantarjian, Hagop; Collins, Robert; R. Patel, Manish; E. Frankel, Arthur; Stein, Anthony; A. Sekeres, Mikkael; T. Swords, Ronan; C. Medeiros, Bruno; Willekens, Christophe; Vyas, Paresh; Tosolini, Alessandra; Xu, Qiang; D. Knight, Robert; E. Yen, Katharine; Agresta, Sam; de Botton, Stephane; S. Tallman, Martin

doi:10.1182/blood-2017-04-779405

Public

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Shared by NobleBlocks on Aug 10, 2017 • 12:00 AM UTC

Authors:

Eytan M. Stein

Courtney D. DiNardo

Daniel A. Pollyea

Abstract

Key Points Enasidenib, a selective inhibitor of mutant IDH2 enzymes, was safe and well tolerated in patients with IDH2-mutated myeloid malignancies. Enasidenib induced hematologic responses in patients with relapsed/refractory AML in this dose-escalation and expansion study.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!